Cellectis Sublicenses Technology to Genoway for Rodent Model-based Research | GenomeWeb

NEW YORK (GenomeWeb News) – Cellectis and Genoway today announced a sublicensing deal covering Cellectis' homologous recombination technology.

The deal makes animal model firm Genoway the exclusive provider of the technology for research applications in genetically modified rodents. Cellectis retains rights to it for all other applications, such as bioproduction and therapeutics. Cellectis licenses the technology from Institut Pasteur.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.